Statement: both the primary trial cohorts receive identical doses of Docetaxel . 8q13-qter is a chromosome band present on 8q
Primary_evidence: INTERVENTION 1:    Docetaxel 100 mg/m^2 Plus Placebo   Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received placebo to bevacizumab intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal. INTERVENTION 2:    Docetaxel 100 mg/m^2 Plus Bevacizumab 7.5 mg/kg   Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received bevacizumab 7.5 mg/kg intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.